Cannabinoid Derived Pharmaceutical Market
完整報告名稱與涵蓋範圍
Cannabinoid Derived Pharmaceutical Market Size, Share & Trends Analysis Report By Product (Natural (Plant-derived), Synthetic Cannabinoid), By Molecule Type (Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), Others), By Disease Indication, By Formulation, By Cannabinoid Type, By Region, And Segment Forecasts, 2025-2034
報告摘要
The Cannabinoid Derived Pharmaceutical Market on a global scale was estimated at USD 12.6 Billion in 2024 and is expected to attain USD 81.1 Billion by 2034, with a projected CAGR of 20.8% between 2025 and 2034.
Cannabinoid Derived Pharmaceutical encompasses naturally occurring compounds derived from the cannabis sativa plant. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cannabinoid Derived Pharmaceutical Market Snapshot
Chapter 4. Global Cannabinoid Derived Pharmaceutical Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Cannabinoid Derived Pharmaceutical Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Cannabinoid Derived Pharmaceutical Market Industry Trends
Chapter 5. Cannabinoid Derived Pharmaceutical Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. Market Share by Products, 2023 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Products:
5.2.1. Natural (Plant-derived)
5.2.1.1. Epidiolex
5.2.1.2. Sativex
5.2.1.3. Other Pipeline Products
5.2.2. Synthetic Cannabinoid
5.2.2.1. Marinol (dronabinol)
5.2.2.2. Syndros (dronabinol)
5.2.2.3. Cesamet (nabilone)
5.2.2.4. Other Pipeline Products
Chapter 6. Cannabinoid Derived Pharmaceutical Market Segmentation 2: By Molecule Type, Estimates & Trend Analysis
6.1. Market Share by Molecule Type, 2023 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
6.2.1. Cannabinoid Receptor Type 1 (CB1)
6.2.2. Cannabinoid Receptor Type 2 (CB2)
6.2.3. Others
Chapter 7. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Disease Indication, Estimates & Trend Analysis
7.1. Market Share by Disease Indication, 2023 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Disease Indication:
7.2.1. Alzheimer's Disease
7.2.2. Autism
7.2.3. Cancer
7.2.4. Chronic Pain
7.2.5. Epilepsy
7.2.6. Migraine
7.2.7. Multiple Sclerosis
7.2.8. Schizophrenia
7.2.9. Others
Chapter 8. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Formulation, Estimates & Trend Analysis
8.1. Market Share by Formulation, 2023 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Formulation:
8.2.1. Oils and Tinctures
8.2.2. Capsules and Tablets
8.2.3. Oral Sprays
8.2.4. Topicals
8.2.5. Others
Chapter 9. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Cannabinoid Type, Estimates & Trend Analysis
9.1. Market Share by Cannabinoid Type, 2023 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Cannabinoid Type:
9.2.1. Cannabidiol (CBD)
9.2.2. Tetrahydrocannabinol (THC)
9.2.3. Others
Chapter 10. Cannabinoid Derived Pharmaceutical Market Segmentation 5: Regional Estimates & Trend Analysis
10.1. Global Cannabinoid Derived Pharmaceutical Market, Regional Snapshot 2023 & 2034
10.2. North America
10.2.1. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.2.3. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.2.4. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.2.5. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.2.6. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.3. Europe
10.3.1. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.3.3. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.3.4. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.3.5. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.3.6. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.4.3. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.4.4. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.4.5. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.4.6. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.5. Latin America
10.5.1. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.5.3. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.5.4. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.5.5. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.5.6. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.6.3. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.6.4. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.6.5. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.6.6. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Arena Pharmaceuticals (Pfizer)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Cannabics Pharmaceuticals Inc.
11.2.3. Cara Therapeutics, Inc.
11.2.4. Cardiol Therapeutics
11.2.5. GW Pharmaceuticals (Jazz Pharmaceuticals)
11.2.6. InMed Pharmaceuticals
11.2.7. INSYS Therapeutics, Inc.
11.2.8. LaraPharm
11.2.9. MGC Pharmaceuticals, Ltd.
11.2.10. One World Cannabis
11.2.11. Orpheus Medica
11.2.12. Receptor Life Sciences
11.2.13. RespireRx Pharmaceuticals
11.2.14. Tetra Bio-Pharma
11.2.15. United cannabis Corporation
11.2.16. Zynerba Pharmaceuticals
11.2.17. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們